Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study

Fig. 2

Survival according to SMI and SMD. SMI status was not associated with OS (median, 6.0 versus 8.0 months in patients with low and high SMI, respectively; P = 0.076) (a) or with PFS (median, 3.3 versus 4.1 months in patients with low and high SMI, respectively; P = 0.752) (b). A low SMD was associated with poorer OS than a high SMD (6.1 vs 7.9 months, P = 0.010) (c), but not with a poorer PFS (3.2 vs 4.2 months, P = 0.116) (d)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us